Lazard Asset Management
RLAY icon

Lazard Asset Management’s Relay Therapeutics RLAY Stock Holding History

Lazard Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
+99,348
New +$1.44M ﹤0.01% 1031
2024
Q4 		– Sell
-818
Closed -$5K – 2499
2024
Q3 		$5K Sell
818
-60,606
-99% -$453K ﹤0.01% 2056
2024
Q2 		$400K Buy
+61,424
New +$420K ﹤0.01% 1295
2024
Q1 		– Sell
-29,669
Closed -$326K – 2326
2023
Q4 		$326K Buy
+29,669
New +$250K ﹤0.01% 1237
2021
Q2 		– Sell
-1,869
Closed -$64K – 2052
2021
Q1 		$64K Buy
+1,869
New +$81.1K ﹤0.01% 1340

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Lazard Asset Management's RLAY Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Relay Therapeutics (RLAY) in Q2 2026: 99,348 shares worth $1.86M. The stake represents ﹤0.01% of the portfolio and ranks #1031 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in RLAY as recently as Q3 2024.

Lazard Asset Management first reported a position in RLAY in Q1 2021 and has held it in 5 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Lazard Asset Management held 99,348 shares of Relay Therapeutics worth $1.86M as of Q2 2026.
  • Relay Therapeutics was a new Lazard Asset Management position in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1031 holding.
  • Lazard Asset Management first reported a position in Relay Therapeutics in Q1 2021 and has held it in 5 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.